Stable angina of coronary heart disease (qi deficiency and blood stasis syndrome)
Conditions
Interventions
Fu Yang also five soup group.:Fuyang wutang granule (op, 1 bag /tid) + capsule simulator (op, 4 grains /tid)
Brain capsule group.:Brain capsule (op, 4 grains /tid) + particle emulsifier (op, 1 bag /tid)
placebo group:Capsule simulant (op, 4 grains /tid) + granulated agent (op, 1 bag /tid)
Sponsors
The Second Affiliated Hospital of Zhejiang Chinese Medical University
Eligibility
Sex/Gender
All
Age
40 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) level in line with the western medicine stability of coronary heart disease angina pectoris ? ~ ? diagnostic criteria; (2) one of the following five items: The coronary angiography showed that at least one coronary artery stenosis was more than 50%. At least one coronary artery stenosis is more than 50%. A history of myocardial infarction; The diagnosis of myocardial nuclide scan was coronary heart disease. The electrocardiogram was positive (male only). (3) meet the diagnostic criteria of TCM syndromes qi deficiency and blood stasis syndrome; (4) has a history of angina pectoris attack, nearly a month or three months ago with myocardial infarction (MI), or do after coronary revascularization therapy for 3 months or application of angina pectoris attack of patients after cardiac pacemaker; (5) between the ages of 40 and 80, gender is not limited; (6) patients with angina disease for 2 months; (7) voluntarily subject to and sign informed consent.
Exclusion criteria
Exclusion criteria: (1) the ST segment of the static ecg was decreased by > 1mm; Coronary heart disease acute myocardial infarction; Severe or patients with angina pectoris IV level; Pulmonary embolism;Aortic dissection; Hypertrophic cardiomyopathy and other types of cardiomyopathy; Aortic stenosis and other valvular disease; Congenital heart disease; Left bundle branch block, digitalis drug influence, electrolyte disturbance, etc.; (2) patients with myocardial infarction (MI) in the last 3 months or patients who had undergone coronary angioplasty or the application of pacemakers within 3 months; (3) severe cardioascular neurosis, menopausal syndrome, cervical spondylosis, and bone and joint disease caused chest pain caused by chest pain and respiratory diseases caused by digestive system diseases; (4) patients with severe cardiopulmonary dysfunction and severe arrhythmia; (5) patients with severe liver and kidney function damage in patients undergoing dialysis (including) and active liver disease (including primary biliary cirrhosis and unexplained persistent abnormal liver function), and/or ALT, AST > 1.5 times the normal limit, Cr > normal limit, TBIL of upper limit of normal or 2 times; (6) patients with other serious cardiovascular and cerebrovascular diseases, liver, kidney, hematopoietic system, and other patients who have undergone major surgery recently are not suitable for this study. (7) persons with mental illness, severe depression, alcohol dependence or history of drug abuse; (8) within 3 months after the pregnancy, lactation period, or during the trial period or after the drug is stopped; (9) allergic constitution or previous allergy to a variety of drugs, or to the study of the ingredients in the drug; (10) participated in other clinical researchers three months before the trial; (11) other researchers considered it inappropriate to participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Symptom score of angina pectoris.; | — |
Secondary
| Measure | Time frame |
|---|---|
| Chinese medicine symptom complex score;Ecg efficacy;Seattle Angina Questionnaire;Nitroglycerin usage.; | — |
Countries
China
Contacts
Public ContactDou Liping
The Second Affiliated Hospital of Zhejiang Chinese Medical University
Outcome results
None listed